IMPACT-MACSNCT07361874
IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Phase changed: Not applicable → Phase 4 Show 5 more changesShow less
- Eligibility criteria expanded, about 103 words
- Primary endpoints: details revised at 1 of 1 entry
- Secondary endpoints: 36 to 56
- Study description expanded, about 95 words
- Publications: details revised at 7 of 8 entries
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Feb 1, 2026 to Mar 5, 2026
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (56)
Show 51 moreShow less
Arms and interventions
Adults with mild autonomous cortisol secretion (MACS) who are clinically eligible for adrenalectomy undergo unilateral adrenalectomy as part of standard clinical care. Participants complete protocol-specified metabolic, hormonal, cardiometabolic, body composition, physical function, and patient-reported outcome assessments through Week 26. Eligible participants may elect to participate in the Optional Extension Phase, with continued follow-up and repeat outcome assessments through Month 12.
Adults with MACS receive semaglutide during the initial 26-week treatment period. Eligible participants who elect to participate in the optional extension phase continue semaglutide treatment and protocol-specified follow-up through Month 12.
Matched adults without adrenal tumors receive semaglutide using the same dosing approach as semaglutide-treated participants with MACS. This arm allows comparison of semaglutide responses between individuals with and without MACS. Eligible matched controls may participate in the Optional Extension Phase through Month 12 if their corresponding matched index participant also elects to participate and both remain eligible for continued study participation.
Procedures: Intervention 1: Adrenalectomy
Drugs: Intervention 2: Semaglutide
Sites
1 site in 1 country
- University of Texas Southwestern Medical CenterDallas, Texas, United States